Validation of Saliva as the Clinical Specimen Type for a University-Wide COVID-19 Surveillance Program
Viruses · 2024
DOI: 10.3390/v16091494 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Viruses, 2024. Verfasst von Michael L Farrell und 14 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Concepts Lab, Georgia Tech Research Institute, Atlanta, GA 30318, USA. Hauptthemen laut MEDLINE: COVID-19, Saliva, Specimen Handling, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: internal resources of the Georgia Tech Research Corporation.
Abstract (Originalsprache)
At the beginning of the COVID-19 pandemic, the Georgia Institute of Technology made the decision to keep the university doors open for on-campus attendance. To manage COVID-19 infection rates, internal resources were applied to develop and implement a mass asymptomatic surveillance program. The objective was to identify infections early for proper follow-on verification testing, contact tracing, and quarantine/isolation as needed. Program success depended on frequent and voluntary sample collection from over 40,000 students, faculty, and staff personnel. At that time, the nasopharyngeal (NP) swab, not saliva, was the main accepted sample type for COVID-19 testing. However, due to collection discomfort and the inability to be self-collected, the NP swab was not feasible for voluntary and frequent self-collection. Therefore, saliva was selected as the clinical sample type and validated. A saliva collection kit and a sample processing and analysis workflow were developed. The results of a clinical sample-type comparison study between co-collected and matched NP swabs and saliva samples showed 96.7% positive agreement and 100% negative agreement. During the Fall 2020 and Spring 2021 semesters, 319,988 samples were collected and tested. The program resulted in maintaining a low overall mean positivity rate of 0.78% and 0.54% for the Fall 2020 and Spring 2021 semesters, respectively. For this high-throughput asymptomatic COVID-19 screening application, saliva was an exceptionally good sample type.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Advanced Concepts Lab, Georgia Tech Research Institute, Atlanta, GA 30318, USA.
- Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332, USA.
- Stamps Student Health Services, Georgia Institute of Technology, Atlanta, GA 30332, USA.
- Animal Health Research Center, Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA.
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30332, USA.
- School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.
ORCID-Profile: Michael L Farrell, Jessica Lin, James T Merrill, Ted M Ross, Robert J Hogan, Greg Gibson, Andrés J García
Förderung
- internal resources of the Georgia Tech Research Corporation
Zitieren
APA
Farrell, M. L., Bryksin, A. V., Ryan, E., Lin, J., Djeddar, N., Khunteev, G., Holton, B., Paca, M., Speller, N., Merrill, J. T., Ross, T. M., Hogan, R. J., Gibson, G., García, A. J., & Shannon, M. P. (2024). Validation of Saliva as the Clinical Specimen Type for a University-Wide COVID-19 Surveillance Program. Viruses. https://doi.org/10.3390/v16091494
Vancouver
Farrell ML, Bryksin AV, Ryan E, Lin J, Djeddar N, Khunteev G, et al. Validation of Saliva as the Clinical Specimen Type for a University-Wide COVID-19 Surveillance Program. Viruses. 2024. doi:10.3390/v16091494
BibTeX
@article{Farrell2024,
author = {Farrell, Michael L and Bryksin, Anton V and Ryan, Emily and Lin, Jessica and Djeddar, Naima and Khunteev, German and Holton, Benjamin and Paca, Miles and Speller, Nicholas and Merrill, James T and Ross, Ted M and Hogan, Robert J and Gibson, Greg and García, Andrés J and Shannon, Michael P},
title = {Validation of Saliva as the Clinical Specimen Type for a University-Wide COVID-19 Surveillance Program},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16091494}
}
EUVIMED